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Summary Very rapid progression of disease with a median survival of 6-9 months is a common feature of metastatic cutaneous malignant
melanoma. Nevertheless, substantial variability of survival suggests that metastatic cutaneous malignant melanoma can be divided into
several biological subgroups. Pretreatment serum levels of soluble adhesion molecules and various clinical parameters in cutaneous
metastatic malignant melanoma were evaluated to determine their prognostic value. In this study pretreatment serum levels of soluble
vascular cell adhesion molecule 1 (sVCAM-1), soluble intercellular cell adhesion molecule 1 (sICAM-1), soluble endothelial leukocyte
adhesion molecule 1 (sE-selectin) and multiple clinical factors were assessed in relation to overall survival of 97 consecutive patients with
metastatic cutaneous malignant melanoma seen at our institution between May 1990 and April 1996. For statistical analysis, both univariate
and multivariate Cox proportional-hazards models were used. Elevated pretreatment serum levels of sVCAM-1 (P < 0.005) and of lactate
dehydrogenase (P < 0.002) were rendered statistically independent and were significantly associated with unfavourable outcome. Patients
were assigned to one of three risk categories (low, intermediate and high) according to a cumulative risk score defined as the function of the
sum of these two variables. There were significant differences in overall survival (P< 0.0001) between low- (n = 53, 5-yearsurvival probability
of 23.3%), intermediate- (n = 29, 5-year survival probability of 9.9%) and high-risk (n = 15) patients. Elevated pretreatment serum levels of
sVCAM-1 and of lactate dehydrogenase correlate with poor outcome in metastatic cutaneous malignant melanoma. These data support risk
stratification for future therapeutic trials and identify factors that need to be validated in prospective studies and may potentially influence
decision-making in palliative management of patients with disseminated cutaneous malignant melanoma.
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O-er the past decade. malignant melanoma has been one of the
most rapidly increasing malignancies in human (Glass and
Hoover. 1989). In the United States, the number of patients with
malignant melanoma nearly doubled between 1980 and 1990
(Grin-Jorgensen et al. 1992). Melanoma frequently affects young
adults and is refractory to current methods oftherapy once dissem-
inated. with a median survival of6-9 months (Legha. 1989: Koh.
1991). Nevertheless. substantial variability of survival suggests
that metastatic malignant melanoma can be divided into several
biological subgroups. Current methods to identify the aggressive
potential ofmetastatic malignant melanoma are limited.
The ability of tumour cells to adhere to and to detach from
extracellular matrix and endothelial cells may be crucial in tumour
invasion and metastasis and may dramatically alter the clinical
outcome for patients with cancer (Albelda, 1993; Gearing and
Newman. 1993: Frenette and Wagner 1996). Several univariate
studies have demonstrated that elevated serum levels of soluble
adhesion molecules correlate with disease progression in malig-
nant melanoma and might serve as prognostic markers (Harming et
al. 1991:Altomonte et al. 1992: Banks et al. 1993).
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Vascular adhesion molecule 1 (VCAM-1. CD106) is a member
of the immunoglobulin superfamily. expressed primarily on
vascular endothelial cells and serves as a counter-receptor for the
integrin a4PI (VLA-4). A soluble isoform ofVCAM-l maintains
the ability to bind VLA-4 and may serve as a mediator in the
metastatic process ofmelanoma cells (Rice and Belivacqua. 1989:
Mould et al. 1994: Garofalo et al. 1995). Intercellular adhesion
molecule 1 (ICAM-1. CD54) is a cell-surface molecule expressed
on a variety ofcell types: a soluble form ofICAM-1 (sICAM-1) is
elevated in inflammation, infection and in cancers. including
malignant melanoma. E-selectin. previously known as endothelial
leukocyte adhesion molecule 1 (CD62e). is particularly inter-
esting. because it is found only on activated endothelial cells. in
contrast to other adhesion molecules. which have a wider tissue
distribution. Endothelial cells have been shown to release E-
selectin (sE-selectin) following in vitro activation (Piggot et al.
1992: Newman et al. 1993). Serum levels ofsE-selectin are signif-
icantly higher in melanoma patients than in normal donors (Fortis
et al. 1995).
We evaluated the prognostic value of elevated serum levels of
soluble adhesion molecules sVCAM-1. sICAM-1. sE-selectin
and ofmultiple clinical parameters in relation to overall survival in
97 consecutive patients with metastatic malignant melanoma
using univariate and multivariate Cox proportional-hazards
models. The purpose of this study was to identify prognostic
factors for survival that may allow appropriate stratification in the
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management of metastatic malignant melanoma both in and
outside clinical trials.
METHODS
Patients and collection of samples
T1his study was approved by the institutional review board of the
Medizinische Hochschule Hannover. written informed consent
was obtained from all patients before entry into the study. At that
time. we obtained samples of peripheral blood from 97 consecu-
tive patients with cutaneous metastatic malignant melanoma, seen
at our institution at the Medizinische Hochschule Hannover.
Germany. since May 1990. Sera were frozen at -70°C until
analysis. Patient charactenrstics are summarized in Table 1: all
patients had a Karnofsky perfornance status >70%7. and presented
with histologically confirmed metastatic malignant melanoma
and clinically progressive disease as demonstrated by standard
radiographic procedures. Patients received chemoimmunotherapy
containing subcutaneous interleukin 2. interferon alpha2a. intra-
venous platinum and dacarbazine with or without carmustine:
treatment was continued until further disease progression occurred
(Atzpodien et al. 1995). Response to therapy was evaluated on an
intention to treat basis and was assessed according to WHO
cnteria.
Enzyme-linked immunosorbent assay (ELISA) for
soluble adhesion molecules
Pretreatment levels of soluble adhesion molecules were deter-
mined using the following ELISA kits: sVCAM-l (Medgenix.
Ratingen. Germany). sICAM-l and sE-selectin (both Quantikine.
R & D. Wiesbaden. Germany). All analyses were performed in
duplicate strictly according to the procedures recommended by the
manufacturers and samples were analysed at a dilution resulting in
measured concentrations within the range of the standard curves.
Normal donor sera were obtained from healthy control subjects
(n = 10): mean serum values ± s.e.m. for sVCAM-l. sICAM-l
and sE-selectin concentrations of the healthy control group
were 509 ngn ml-' + 14 ng ml-'. 208 ng ml-' + 12 ng ml-'. and
54 ng ml + 7 ng ml-' respectively.
Statistical analysis
The statistical end point in our analysis was overall survival from
time ofentry into the study. We calculated univariate hazard ratios
with 95% confidence intervals. using the Cox proportional-
hazards model (Cox. 1972). The simultaneous prognostic effect of
various factors was determined in amultivariate analysis using the
Cox proportional-hazards model (forward selection of variables).
The probability of overall survival was plotted over time
according to the method of Kaplan and Meier (Kaplan and Meier.
1958). Differences between groups in overall survival were tested
with Breslow statistics. Clinical parameters and soluble adhesion
molecules were tested as dichotomized prognostic variables. For
age. time since tumour progression. time since tumour diagnosis.
erythrocyte sedimentation rate (ESR). neutrophil count. haemo-
globin. sICAM-1. sVCAM-1 and sE-selectin, Kaplan-Meier esti-
mates were performed. defining the best cut-off value as the value
that best discriminates between poor and good overall survival.
For lactate dehydrogenase (LDH) and C-reactive protein (CRP).
Table 1 Patient characteristics and risk categones according to elevated
serum levels of soluble VCAM-1 and LDH
Variable Toal Low Intermediate High
risk risk risk
No.of pafieft
Sex
Male 61 33 18 10
Female 36 20 11 5
Age (years)
Mean 52.2 50.5 53.2 54.3
Range 20-73 20-71 23-73 29-73
Histological subtype
Superficial spreading 24 10 10 4
Amelanotic 16 7 3 6
Nodular 21 12 8 1
Acral lentiginous 3 2 1 0
Unclaified cutaneous 33 22 7 4
Metastases
Skin, subcutaneoustissues, 65 33 20 12
distant lymph nodes
Visceral metastases 54 21 22 11
Lung metastases 40 18 16 6
Brain metastases 4 0 3 1
Bone metastases 9 4 4 1
Other 12 1 5 6
Patients were assigned to one of three risk categories (low, intermediate or
high) according to cumulative rsk, defined as the functon of the sum of two
independent variables, i.e. elevated serum levels of sVCAM-1 (> 770 ng ml)
and LDH (> 240 U et).
the institutional upper normal limits w-ere chosen as cut-off
(< 240 U 1-' and < 8 mg 1-1 respectixely).
RESULTS
Univanate analysis of pretreatment variables and
survival
We analysed the ability of various clinical factors and of levels of
soluble adhesion molecules to predict clinical outcome. The mean
penod of follow-up for the surviving patients was 21 months
(range 1-67 months). The median survival of all 97 patients
entering the study was 10 months.
We calculated univariate hazard ratios with the Cox propor-
tional-hazards model (Table 2). In this analysis. LDH. ESR. the
presence of visceral metastases. liver disease and the number of
metastatic sites had significant prognostic value with regard to
overall survival. Elevated serum levels ofLDH (> 240 U 1-') were
present in 39 patients and were strongly associated with an
unfavourable outcome: median survival in these patients was 5
months as opposed to patients with normal serum LDH (n = 58).
who had a median survival of 16 months (P < 0.0001. Figure 1). A
tendency towards higher serum levels of LDH was found in
patients with liver metastases (P = 0.001. chi-square test). Liver
metastases were an important prognostic factor when examined by
single-factor analysis (P < 0.004) and by multivariate analysis
(P < 0.04). The median survival for patients with liver metastases
was 6 months. compared with 11 months for patients without liver
metastases. In general. only visceral disease was of significant
prognostic value in univariate analysis (P = 0.004). It is notable
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Table 2 Hazard ratis associated with pretreatment clinical factors and soluble adhesion molecule levels in 97 consecutive patients with
disseminated cutaneous malignant melanoma
Hazard ratio
(95%)
Variable Categorles compareda confidence PLvalueb
interval)
Clinical factors
Sex Female vs. mnale 0.99 (0.79-1.25) 0.93
Age (years) < 60 vs > 60 1.01 (0.80-1.28) 0.91
Time since tumour progression (months) < 10 vs > 10 1.17 (0.91-1.51) 0.21
Time since tumour diagnosis (months) < 24 vs > 24 1.05 (0.80-1.38) 0.73
Liver metastases Absent vs present 0.71 (0.55-0.90) < 0.004
Visceral metastases Absent vs present 0.69 (0.55-0.87) 0.004
Lung metastases Absent vs present 0.87 (0.69-1.09) 0.2
Brain metastases Absent vs present 0.62 (0.37-1.03) 0.05
Bone metastases Absent vs present 0.86 (0.59-1.28) 0.45
Skin, subcutareous, tissue metastases Absent vs present 0.92 (0.73-1.17) 0.5
Metastatic sites One site vs more than one site 0.72 (0.57-0.91) 0.003
ESR (mm h-1) < 50 vs > 50 0.67 (0.51-0.87) 0.001
CRP (mg V-) < 8 vs > 8 0.79 (0.63-1.0) 0.05
LDH (U 1-) < 240 vs > 240 0.58 (0.46-0.73) < 0.0001
Neutrophil count (celIs 1IV) < 6000 vs > 6000 0.99 (0.74-1.32) 0.91
Haemoglobin (g dl- ) < 10 vs > 10 1.16 (0.78-1.71) 0.44
Adhesion monecules < 770 vs > 770 0.58 (0.44-0.75) < 0.0001
sVCAM-1 (ng ml-)
sICAM-1 (ng ml-') < 290 vs > 290 0.73 (0.57-0.92) < 0.005
sE-selectin (ng ml-') < 60 vs > 60 0.77 (0.61-0.97) 0.02
aFor each variable, the prognostic significance of the first category listed was assessed bycomnparingthat category with the reference category
(the second category listed). "For the comparison of the hazard ratio shown with a hazard ratio of 1.0 (as postulated by the null hypothesis).
that brain. lung and bone metastases were not associated with a
poorer clinical outcome. Patients with brain metastases only were
allowed to receive simultaneously radiationtherapy to the brain. It
is likely that palliative radiation therapy to the brain resulted in a
longenough survivalto allow other factors to be moreimportant in
predicting the clinical course of disease. Patients with a single
metastasis survived longer than patients with metastases at two or
more sites (P = 0.003). The median survival was 14 months for
patients with one metastatic site and 7 months for those with more
than one metastatic site. Time since tumour progression and since
tumour diagnosis was not rendered statistically significant in
predicting overall survival (P = 0.21 and P = 0.73 respectively).
Once melanoma progressed to distant metastases, there was no
correlation between the sex/age of the patient and the clinical
course (P = 0.93 and P = 0.91 respectively): survival curves were
superimposable. There were nohistological criteria ofthe primary
melanomas that predicted the patients' clinical courses once they
developed distant metastases.
All adhesion molecules tested had significant prognostic value.
Elevated serum levels of sVCAMI-l (> 770 ng ml-. n = 20) were
associated with the highest likelihood of an unfavourable outcome.
The median survival for these patients was very poor (5 months) as
opposed to patients in whom no elevated sVCAM-1 levels were
observed (median survival 12 months. n = 57. P <0.0001. Figure 2).
Similarly, patients with elevated serum levels of sICAM-1
(.290 ng ml-. n = 56. median survival. 6months) andpatients with
elevated serum levels of sE-selectin (260 ng ml-'. n = 32. median
survival. 6 months) had a reduced overall survival when compared
with patients without elevated sICAM-l and sE-selectin respec-
tively (median survival 16 and 13 months respectively. P <0.02).
Multivariate analysis of risk factors
To identify the most powerful prognostic factors. we established a
multivariate Cox proportional-hazards model containing those
factors with significant prognostic value upon univariate analysis.
The following three factors were found to be significant: liver
metastases (P < 0(04). serum LDH (P <0.002) and sVCAM-l
(P < 0.005). The hazard ratios calculated with a model containing
these prgnostic factors are shown in Table 3. Factors also evaluated
and found not to be independent by multivariate analyses included
evaluated ESR. visceral disease, more than one metastatic site.
sICAM and sE-selectin. These results were the same even after
accounting for palliative chemotherapy. This complex model
resulted in numerousprognostic subgroups ofsmall sizes and, there-
fore. it appeared inappropriate for further statistical verification.
Development of a cumulative risk model
On the basis of those two pretreatment prognostic parameters of
highest statistical significance. which were rendered independent
upon multivariate analysis. i.e. elevated serum levels ofsVCAM- 1
and LDH. patients were assigned to one of three nrsk categories:
low risk.defined as the absence of either risk factor: intermediate
risk. defined as the presence of one risk factor: and high risk.
defined as the presence ofboth risk factors (Figure 3). There were
significant differences in overall survival (P < 0.0001) between
low-risk (n = 53,median survival 16 months. 5-year survival prob-
ability 23.3%). intermediate-risk (n = 29. median survival 6
months. 5-year survival probability 9.9%c) and high-risk patients
(n = 15. median survival 5 months. 5-year survival probability
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Figure 1 LDH and survival in 97 patients with metastatic cutaneous
malignant melanoma. Survival curves (Kapan-Meer estimate) of patients
with either low (< 240 U h) or elevated (.240 U V) serum levels of LDH.
P-value was determined by klo-rank test. Tick marks represent patients for
whom data were censored
0%). The intermediate nrsk group consisted of five patients with
elevated sVCAM-1 lexels and 24 patients with elevated LDH. The
median survival for both subgroups showed no statistically signif-
icant difference. None of the metastatic cutaneous malignant
melanoma patients at high risk survived for more than one year.
DISCUSSION
Our study found that elevated pretreatment serum sVCAM-1 is a
potentially powerful prognostic indicator of overall survival in
patients with metastatic cutaneous malignant melanoma. By
univariate analysis. the most significant prognostic variables were
(1) serum LDH. (2) erythrocyte sedimentation rate. (3) the pres-
ence of visceral metastases. (4) the presence of liver metastases.
(5) more than one metastatic site and (6) elevated serum levels of
soluble adhesion molecules VCAM-1. ICAM-1 and E-selectin.
Multivariate analysis showed that elevated serum levels of
sVCAM-I (P < 0.005) and ofLDH (P < 0.002) were the dominant
independent prognostic variables. When combining elevated
sVCAM-1 and serum LDH we were able to identify a subgroup of
patients at highestnrsk. all ofwhom died ofdisease within 1 year. In
contrast. intermediate-risk patients exhibiting one of the two
pretreatment risk factors reached a 5-year survival probability of
10%. whereas median survival was similar to high-risk patients. In
comparison with high- and intermediate-risk patients, the subgroup
at lowest risk demonstrated a median survival of 16 months and a
5-year survival probability of 23%. This risk stratification
suggested that metastatic cutaneous malignant melanoma patients
can be divided into several biological subgroups: however. the
present model needs to be validated in prospective trials.
LDH has been reported as a prognostic parameter in metastatic
malignant melanoma, in correlation with tumour burden (Heimdal
et al. 1989: Sirott et al. 1993). An elevated serum LDH does not
necessarily indicate liver metastasis. In this study. 40% ofpatients
had elevated serum levels of LDH. but only 26% had confirmed
liver metastases. Moreover, serum LDH and the presence of liver
metastases were independent prognostic markers upon multi-
variate analysis. The reduced survival of patients with more than
one metastatic site confirms the findings of Balch et al (1983).
However. in the present study the number of metastatic sites was
not of independent significance. This may be explained in part by
sVCAM-1 (n= 57)
12 24 36 48 60 72 84
Time (months)
Figure 2 sVCAM-1 and survival in 97 patients with metastatic cutaneous
malignant melanoa. Survival curves (Kaplan-Meler estimate) of patients
with either low (< 770 ng ml-) or elevated (> 770 ng ml') serum levels of
sVCAM-1. P-value was determined by log-rank test. Tick marks represent
patients for whom data were censored
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Figure 3 Kaplan-Meler curves of patient categones stratified according to
cumulative risk of elevated pretreatment serum sVCAM-1 and LDH in 97
patients with metastatic cutaneous malignant melarnoa. The study
population of patents wih metastatic cutaneous malignant melarnma was
analysed according to elevated pretreatment serum levels of sVCAM-1 and
LDH. Patients were assigned to one of three risk categories according to
cumulative risk, defined as the functon of the sum of two independent
varables, i.e. elevated serum levels of sVCAM-1 (> 770 ng ml-) and LDH
(> 240 U h1). P-value was determined by og-rank test. lick marks represent
patients for whom data were censored
the inclusion of serum LDH in this study. which achieved statis-
tical significance as a more accurate marker of tumour burden.
Erythrocyte sedimentation rate, which is a known unspecific
marker in various human malignancies, did not reach statistical
independence in the prognosis ofmetastatic malignant melanoma
We were able to confirrm and extend earlier reports of elevated
serum levels of sICAM-1 and sE-selectin in metastatic malignant
melanoma patients. Although in this multivariate analysis. sE-
selectin and sICAM-1 were of no prognostic xalue. sVCAM-1
presented as an independent predictor of survival for patients with
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Table 3 Hazard ratios associated with pretreatment prognostic factors in a multivariate analysis of 97 consecutive patients with cutaneous
malIgnant metastatic melanoma, using Cox proporbonal-hazards models
Hazard ratio
(95%
Variables Categories collar confidence P-valuec
lnteval)
Clinical factors
Liver metastases Absent vs present 0.76 (0.59-0.97) < 0.04
LDH (U h) < 240 vs . 240 0.61 (0.48-0.79) < 0.002
Adhesion rmoLecules < 770 vs > 770 0.71 (0.54-0.95) < 0.005
sVCAM-1 (ng ml-')
aFactors also evaluated and rernered not independent by multvanate analysis included elevated ESR, more than one metastatic site, visceral
metastases, sICAM-1 and sE-seiectin. +For each variable, the prognosbc significance of the first category listed was assessed by comparing
that category with the reference category (the second category listed). cFor the companson of the hazard rato shown with a hazard ratio of 1.0
(as postulated by the null hypothesis).
metastatic cutaneous malignant melanoma. Notably. in the present
study. pretreatment elevation of sVCAM-1 was most probably not
due to tumour burden as suggested by its statistical independence
upon multivariate analysis. The differences in prognostic value
with regard to sVCAM-1. sICAM-1 and sE-selectin probably
reflect differences in source. kinetics of expression and signals
inducing adhesion molecule shedding. The significance ofadhesion
molecule shedding is not clear but may have profound implications
for tumour metastasis. In malignant melanoma. a401 integnn
(VLA-4) mediates melanoma cell adhesion and migration through
binding to VCAM-1 (Mould et al. 1994: Schadendorf et al. 1995).
Conversely, down-regulation of VCAM-1 on endothelial cells has
been identified as a potential mechanism ofmelanoma escape from
cytotoxic lymphocyte surveillance (Piali et al. 1995).
Several other preclinical parameters have been reported as
prognostic variables in metastatic malignant melanoma. Primary
tumour- or metastasis-related parameters include cytogenetic
abnormalities. DNA ploidy and S-phase fraction, the expression of
metastasis associated gene products. the S100 protein and the
detection of circulating melanoma cells in peripheral blood using
reverse transcriptase-polymerase chain reaction (RT-PCR) for
tyrosinase messenger RNA (Trent et al. 1990; Smith et al. 1991;
Xerri et al. 1994: Karlson et al. 1996: Kunter et al. 1996: Buer et
al. 1997). Although all of these malignant melanoma-associated
features reflect isolated aspects of tumour biology, in the present
study we were able to define a new and highly specific parameter
potentially indicative of tumour cell-extracellular matrix inter-
action and its impact on survival in malignant melanoma.
In conclusion. elevated pretreatment serum levels of sVCAM-1
and of LDH correlate with poor outcome in cutaneous metastatic
malignant melanoma. These data support risk stratification for
future therapeutic trials. and identify factors that may potentially
influence decision-making in palliative management of patients
with disseminated malignant melanoma. In addition. an improved
understanding ofthe endothelial matrix-associated mechanisms of
tumour cell adhesion and invasion may provide a lead for future
therapeutic strategies focusing on the regulation of endothelial
function and damage in human malignancies. Ourresults will have
to be confirmed prospectively in future controlled studies.
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